Matthew Porteus
Geen lopende functies
Vermogen: 11 M $ op 31-03-2024
Profiel
Matthew Porteus is the founder of CRISPR Therapeutics AG, which was founded in 2013.
He is also the founder of Graphite Bio, Inc., which was founded in 2017.
Dr. Porteus's current job is as a Professor at Stanford University and as an Associate Professor at Stanford School of Medicine since 2010.
His former job was as an Assistant Professor at The University of Texas Southwestern Medical Center from 2003 to 2010.
Dr. Porteus's education includes an undergraduate degree from Harvard University and a doctorate from Stanford University.
Dr. Porteus is also the founder of Kamau Therapeutics, Inc...
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
1.97% | 01-02-2024 | 504 075 ( 1.97% ) | 11 M $ | 31-03-2024 |
Actieve functies van Matthew Porteus
| Bedrijven | Functie | Begin |
|---|---|---|
| Stanford School of Medicine | Corporate Officer/Principal | 01-10-2010 |
| Stanford University | Corporate Officer/Principal | - |
Eerdere bekende functies van Matthew Porteus
| Bedrijven | Functie | Einde |
|---|---|---|
| The University of Texas Southwestern Medical Center | Corporate Officer/Principal | 01-08-2010 |
| LENZ THERAPEUTICS, INC. | Founder | - |
| CRISPR THERAPEUTICS AG | Founder | - |
Opleiding van Matthew Porteus
| Harvard University | Undergraduate Degree |
| Stanford University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| CRISPR THERAPEUTICS AG | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Graphite Bio, Inc.
 Graphite Bio, Inc. BiotechnologyHealth Technology Graphite Bio, Inc. is a clinical-stage gene editing company. It engages in the business of developing therapies that harness targeted gene integration to treat or cure serious diseases. The company was founded by Matthew Porteus and Maria Grazia Roncarolo on June 1, 2017 and is headquartered in South San Francisco, CA. | Health Technology |
